In the past, the airway epithelium was thought to be primarily an inert physical barrier. We now know that the upper airway epithelium plays a critical role in both innate and adaptive immunity, and that epithelial dysfunction is strongly associated with inflammatory airway disease. The pathogenesis of chronic rhinosinusitis is poorly understood, but growing evidence supports a key role for the airway epithelium in the pathophysiology of the disease.
Objective
The purpose of this study is to explore our current understanding of how dysfunction in human sinonasal epithelial cells (HSNECs) contributes to the pathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNP) and to examine how current and developing therapies affect epithelial cell functions.
Methods
A literature review of papers published in English pertaining to epithelial cell dysfunction in patients with CRSwNP was performed using the PubMed database. The search utilized combinations of the following key words: sinusitis, polyps, epithelium, pathophysiology, barrier function, dendritic cells, eosinophils, T cells, complement, mucociliary clearance, vitamin D, cytokines, chemokines, taste receptors, steroids, saline, and therapy.
Results
HSNEC mucociliary clearance, barrier function, secretion of cytokines, influence on dendritic cells, influence on T-cells, regulation of eosinophils, vitamin D metabolism, complement production, and taste receptor function are altered in patients with CRSwNP and contribute to the pathogenesis of the disease. Current therapies utilized to manage CRSwNP counteract the effects of HSNEC dysfunction and relieve key symptoms of the disease.
Conclusion
HSNECs are key players in both innate and adaptive immunity, and altered epithelial functions are closely intertwined with the pathogenesis of CRSwNP. Our review supports further investigation of altered HSNEC function in patients with CRSwNP and supports development of novel epithelial-targeted therapies for its management.
FokkensWJLundVJMullolJ, et al.
EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists.Rhinology. 2012;
50:1–12.
2.
KatoA.Immunopathology of chronic rhinosinusitis.Allergol Int. 2015;
64:121–130.
KhalmuratovaRParkJWShinHW.Immune cell responses and mucosal barrier disruptions in chronic rhinosinusitis.Immune Netw. 2017;
17:60–67.
5.
HopkinsCBrowneJPSlackR, et al.
The national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis.Clin Otolaryngol. 2006;
31:390–398.
6.
SteinNRJafariA. Revision rates and time to revision following endoscopic sinus surgery: a large database analysis. 2018;128:31–36.
7.
WynnRHar-ElG.Recurrence rates after endoscopic sinus surgery for massive sinus polyposis.Laryngoscope. 2004;
114:811–813.
8.
CalusLVan BruaeneNBosteelsC, et al.
Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis.Clin Transl Allergy. 2019;
9:30.
9.
PhilpottCHopkinsCErskineS, et al.
The burden of revision sinonasal surgery in the UK-data from the Chronic Rhinosinusitis Epidemiology Study (CRES): a cross-sectional study.BMJ Open. 2015;
5:e006680.
10.
MiglaniADivekarRDAzarA, et al.
Revision endoscopic sinus surgery rates by chronic rhinosinusitis subtype.Int Forum Allergy Rhinol. 2018;
8:1047–1051.
11.
GanesanSComstockATSajjanUS.Barrier function of airway tract epithelium.Tissue Barriers. 2013;
1:e24997.
12.
MainaIWWorkmanADCohenNA.The role of bitter and sweet taste receptors in upper airway innate immunity: recent advances and future directions.World J Otorhinolaryngol Head Neck Surg. 2018;
4:200–208.
13.
PassaliDFerriRBecchiniG, et al.
Alterations of nasal mucociliary transport in patients with hypertrophy of the inferior turbinates, deviations of the nasal septum and chronic sinusitis.Eur Arch Otorhinolaryngol. 1999;
256:335–337.
14.
HuaXNaselskyWCBennettWD, et al.
Adenosine increases nasal mucociliary clearance rate in mice through A2A and A2B adenosine receptors.Laryngoscope. 2013;
123:306–310.
15.
ElwanySHishamMGamaeeR.The effect of endoscopic sinus surgery on mucociliary clearance in patients with chronic sinusitis.Eur Arch Otorhinolaryngol. 1998;
255:511–514.
16.
HamilosDL.Host-microbial interactions in patients with chronic rhinosinusitis.J Allergy Clin Immunol. 2014;
133:640–653.e644.
17.
ChenBShaariJClaireSE, et al.
Altered sinonasal ciliary dynamics in chronic rhinosinusitis.Am J Rhinol. 2006;
20:325–329.
18.
ZhaoK-QCowanATLeeRJ, et al.
Molecular modulation of airway epithelial ciliary response to sneezing.FASEB J. 2012;
26(8):3178–3187.
19.
OstrowskiLEYinWRogersTD, et al.
Conditional deletion of dnaic1 in a murine model of primary ciliary dyskinesia causes chronic rhinosinusitis.Am J Respir Cell Mol Biol. 2010;
43:55–63.
20.
ZhangNVan CrombruggenKGevaertE, et al.
Barrier function of the nasal mucosa in health and type-2 biased airway diseases.Allergy. 2016;
71:295–307.
21.
KojimaTGoMTakanoK, et al.
Regulation of tight junctions in upper airway epithelium.BioMed Res Int.
2013;2013:947072.
22.
KnightDAHolgateST.The airway epithelium: structural and functional properties in health and disease.Respirology (Carlton, Vic). 2003;
8:432–446.
23.
LiYWangXWangR, et al.
The expression of epithelial intercellular junctional proteins in the sinonasal tissue of subjects with chronic rhinosinusitis: a histopathologic study.ORL J Otorhinolaryngol Relat Spec. 2014;
76:110–119.
24.
SoykaMBWawrzyniakPEiweggerT, et al.
Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-gamma and IL-4.J Allergy Clin Immunol. 2012;
130:1087–1096.e1010.
25.
WiseSKLauryAMKatzEH, et al.
Interleukin-4 and interleukin-13 compromise the sinonasal epithelial barrier and perturb intercellular junction protein expression.Int Forum Allergy Rhinol. 2014;
4:361–370.
26.
JiaoJWangMDuanS, et al.
Transforming growth factor-β1 decreases epithelial tight junction integrity in chronic rhinosinusitis with nasal polyps.J Allergy Clin Immunol. 2018;
141:1160–1163.e1169.
27.
LamMHullLMcLachlanR, et al.
Clinical severity and epithelial endotypes in chronic rhinosinusitis.Int Forum Allergy Rhinol. 2013;
3:121–128.
28.
NagarkarDRPoposkiJATanBK, et al.
Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis.J Allergy Clin Immunol. 2013;
132:593–600.e512.
29.
KitajimaMLeeHCNakayamaT, et al.
TSLP enhances the function of helper type 2 cells.Eur J Immunol. 2011;
41:1862–1871.
30.
ZhangLJiangLLCaoZW.Interleukin-33 promotes the inflammatory reaction in chronic rhinosinusitis with nasal polyps by NF-kappaB signaling pathway.Eur Rev Med Pharmacol Sci. 2017;
21:4501–4508.
31.
CaoPPShiLLXuK, et al.
Dendritic cells in inflammatory sinonasal diseases.Clin Exp Allergy. 2016;
46:894–906.
32.
MulliganJKMulliganRMAtkinsonC, et al.
Human sinonasal epithelial cells direct dendritic function and T-cell T helper 1/T helper 2 skewing following Aspergillus exposure.Int Forum Allergy Rhinol. 2011;
1:268–274.
33.
GeorasSNRezaeeF.Epithelial barrier function: at the front line of asthma immunology and allergic airway inflammation.J Allergy Clin Immunol. 2014;
134:509–520.
34.
DeryckeLEyerichSVan CrombruggenK, et al.
Mixed T helper cell signatures in chronic rhinosinusitis with and without polyps.PLoS One. 2014;
9:e97581.
35.
Van ZeleTClaeysSGevaertP, et al.
Differentiation of chronic sinus diseases by measurement of inflammatory mediators.Allergy. 2006;
61:1280–1289.
36.
HulseKEStevensWWTanBK, et al.
Pathogenesis of nasal polyposis.Clin Exp Allergy. 2015;
45:328–346.
37.
StevensWWOcampoCJBerdnikovsS, et al.
Cytokines in chronic rhinosinusitis. role in eosinophilia and aspirin-exacerbated respiratory disease.Am J Respir Crit Care Med. 2015;
192:682–694.
38.
ChoDYNayakJVBravoDT, et al.
Expression of dual oxidases and secreted cytokines in chronic rhinosinusitis.Int Forum Allergy Rhinol. 2013;
3:376–383.
39.
ZhangPMartinMYangQB, et al.
Role of B7 costimulatory molecules in immune responses and T-helper cell differentiation in response to recombinant HagB from Porphyromonas gingivalis.Infect Immun. 2004;
72:637–644.
40.
KimJMyersACChenL, et al.
Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells.Am J Respir Cell Mol Biol. 2005;
33:280–289.
41.
SchleimerRPKatoAKernR, et al.
Epithelium: at the interface of innate and adaptive immune responses.J Allergy Clin Immunol. 2007;
120:1279–1284.
42.
FokkensWLundVMullolJ.European position paper on rhinosinusitis and nasal polyps 2007. Rhinol Suppl. 2007;
20:1–136.
43.
WenTRothenbergME.The regulatory function of eosinophils.Microbiol Spectr. 2016;
4:10.1128/microbiolspec.MCHD-0020-2015.
44.
DavoineFLacyP.Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity.Front Immunol. 2014;
5:570–570.
45.
SnidvongsKLamMSacksR, et al.
Structured histopathology profiling of chronic rhinosinusitis in routine practice.Int Forum Allergy Rhinol. 2012;
2:376–385.
46.
HauserLJChandraRKLiP, et al.
Role of tissue eosinophils in chronic rhinosinusitis-associated olfactory loss.Int Forum Allergy Rhinol. 2017;
7:957–962.
47.
SolerZMSauerDMaceJ, et al.
Impact of mucosal eosinophilia and nasal polyposis on quality-of-life outcomes after sinus surgery.Otolaryngol Head Neck Surg. 2010;
142:64–71.
48.
TosunFArslanHHKarsliogluY, et al.
Relationship between postoperative recurrence rate and eosinophil density of nasal polyps.Ann Otol Rhinol Laryngol. 2010;
119:455–459.
49.
KatoA.Immunopathology of chronic rhinosinusitis.Allergol Int. 2015;
64:121–130.
50.
OlzeHForsterUZuberbierT, et al.
Eosinophilic nasal polyps are a rich source of eotaxin, eotaxin-2 and eotaxin-3.Rhinology. 2006;
44:145–150.
51.
LamMHullLImrieA, et al.
Interleukin-25 and interleukin-33 as mediators of eosinophilic inflammation in chronic rhinosinusitis.Am J Rhinol Allergy. 2015;
29:175–181.
52.
OuyangYFanELiY, et al.
Clinical characteristics and expression of thymic stromal lymphopoetin in eosinophilic and non-eosinophilic chronic rhinosinusitis.ORL J Otorhinolaryngol Relat Spec. 2013;
75:37–45.
53.
MagisterSKosJ.Cystatins in immune system.J Cancer. 2012;
4:45–56.
54.
YanBLouHWangY, et al. Epithelium-derived cystatin-SN enhances eosinophil activation and infiltration via interleukin-5 in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2019; 144(2): 455–469. doi:10.1016/j.jaci.2019.03.026
55.
MulliganJKPasquiniWNCarrollWW, et al.
Dietary vitamin D3 deficiency exacerbates sinonasal inflammation and alters local 25(OH)D3 metabolism.PLoS One. 2017;
12:e0186374.
56.
MulliganJKNagelWO’ConnellBP, et al.
Cigarette smoke exposure is associated with vitamin D3 deficiencies in patients with chronic rhinosinusitis.J Allergy Clin Immunol. 2014;
134:342–349.
57.
SchlosserRJCarrollWWSolerZM, et al.
Reduced sinonasal levels of 1alpha-hydroxylase are associated with worse quality of life in chronic rhinosinusitis with nasal polyps.Int Forum Allergy Rhinol. 2016;
6:58–65.
58.
KhareDGodboleNMPawarSD, et al.
Calcitriol [1, 25[OH]2 D3] pre- and post-treatment suppresses inflammatory response to influenza A (H1N1) infection in human lung A549 epithelial cells.Eur J Nutr. 2013;
52:1405–1415.
59.
WalportMJ.Complement. First of two parts.N Engl J Med. 2001;
344:1058–1066.
60.
WalportMJ.Complement. Second of two parts.N Engl J Med. 2001;
344:1140–1144.
61.
KolevMLe FriecGKemperC.The role of complement in CD4(+) T cell homeostasis and effector functions.Semin Immunol. 2013;
25:12–19.
62.
HeegerPSKemperC.Novel roles of complement in T effector cell regulation.Immunobiology. 2012;
217:216–224.
63.
HeegerPSLalliPNLinF, et al.
Decay-accelerating factor modulates induction of T cell immunity.J Exp Med. 2005;
201:1523–1530.
64.
LiszewskiMKKolevMLe FriecG, et al.
Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation.Immunity. 2013;
39:1143–1157.
65.
SchlosserRJMulliganRMCaseySE, et al.
Alterations in gene expression of complement components in chronic rhinosinusitis.Am J Rhinol Allergy. 2010;
24:21–25.
66.
JunSWKimTHLeeHM, et al.
Overexpression of the anaphylatoxin receptors, complement anaphylatoxin 3a receptor and complement anaphylatoxin 5a receptor, in the nasal mucosa of patients with mild and severe persistent allergic rhinitis.J Allergy Clin Immunol. 2008;
122:119–125.
67.
ShamriRXenakisJJSpencerLA.Eosinophils in innate immunity: an evolving story.Cell Tissue Res. 2011;
343:57–83.
68.
LaneAPTruong-TranQAMyersA, et al.
Serum amyloid A, properdin, complement 3, and toll-like receptors are expressed locally in human sinonasal tissue.Am J Rhinol. 2006;
20:117–123.
69.
MulliganJKPatelKWilliamsonT, et al.
C3a receptor antagonism as a novel therapeutic target for chronic rhinosinusitis.Mucosal Immunol. 2018;
11:1375–1385.
70.
AdappaNDFarquharDPalmerJN, et al.
TAS2R38 genotype predicts surgical outcome in nonpolypoid chronic rhinosinusitis.Int Forum Allergy Rhinol. 2016;
6:25–33.
71.
AdappaNDZhangZPalmerJN, et al.
The bitter taste receptor T2R38 is an independent risk factor for chronic rhinosinusitis requiring sinus surgery.Int Forum Allergy Rhinol. 2014;
4:3–7.
72.
LeeRJXiongGKofonowJM, et al.
T2R38 taste receptor polymorphisms underlie susceptibility to upper respiratory infection.J Clin Invest. 2012;
122:4145–4159.
73.
LeeRJXiongGKofonowJM, et al.
T2R38 taste receptor polymorphisms underlie susceptibility to upper respiratory infection.J Clin Invest. 2012;
122:4145–4159.
74.
WorkmanADBrooksSGKohanskiMA, et al.
Bitter and sweet taste tests are reflective of disease status in chronic rhinosinusitis.J Allergy Clin Immunol Pract. 2018;
6:1078–1080.
75.
WorkmanADMainaIWBrooksSG, et al.
The role of quinine-responsive taste receptor family 2 in airway immune defense and chronic rhinosinusitis.Front Immunol. 2018;
9:624.
76.
CareyRMWorkmanADYanCH, et al.
Sinonasal T2R-mediated nitric oxide production in response to Bacillus cereus.Am J Rhinol Allergy. 2017;
31:211–215.
77.
LiDShirakamiGZhanX, et al.
Regulation of ciliary beat frequency by the nitric oxide-cyclic guanosine monophosphate signaling pathway in rat airway epithelial cells.Am J Respir Cell Mol Biol. 2000;
23:175–181.
78.
HaldermanALaneAP.Genetic and immune dysregulation in chronic rhinosinusitis.Otolaryngol Clin N Am. 2017;
50:13–28.
79.
CainRBLalD.Update on the management of chronic rhinosinusitis. Infect Drug Resist. 2013;
6:1–14.
80.
RudmikLHoyMSchlosserRJ, et al.
Topical therapies in the management of chronic rhinosinusitis: an evidence-based review with recommendations.Int Forum Allergy Rhinol. 2013;
3:281–298.
81.
MullolJXaubetAGayaA, et al.
Cytokine gene expression and release from epithelial cells. A comparison study between healthy nasal mucosa and nasal polyps.Clin Exp Allergy. 1995;
25:607–615.
82.
XaubetAMullolJLopezE, et al.
Comparison of the role of nasal polyp and normal nasal mucosal epithelial cells on in vitro eosinophil survival. Mediation by GM-CSF and inhibition by dexamethasone.Clin Exp Allergy. 1994;
24:307–317.
83.
GrzankaAMisiolekMGolusinskiW, et al.
Molecular mechanisms of glucocorticoids action: implications for treatment of rhinosinusitis and nasal polyposis.Eur Arch Otorhinolaryngol. 2011;
268:247–253.
84.
LeeSH.Mechanisms of glucocorticoid action in chronic rhinosinusitis.Allergy Asthma Immunol Res. 2015;
7:534–537.
85.
LiPLiYLiYQ, et al.
Glucocorticoid receptor expression and glucocorticoid therapeutic effect in nasal polyps.Clin Invest Med. 2010;
33:E181–E188.
86.
WatanabeSSuzakiH.Changes of glucocorticoid receptor expression in the nasal polyps of patients with chronic sinusitis following treatment with glucocorticoid. In vivo (Athens, Greece). 2008;
22:37–42.
87.
HamilosDLLeungDYMuroS, et al.
GRbeta expression in nasal polyp inflammatory cells and its relationship to the anti-inflammatory effects of intranasal fluticasone.J Allergy Clin Immunol. 2001;
108:59–68.
88.
ValeraFCScrideliCQueinozR, et al.
NF-kappaB expression predicts clinical outcome for nasal polyposis.Rhinology. 2010;
48:408–441.
89.
PujolsLAlobidIBenítezP, et al.
Regulation of glucocorticoid receptor in nasal polyps by systemic and intranasal glucocorticoids. Allergy. 2008;
63(10):1377–1386.
90.
ChoiB-RKwonJHGongS-J, et al.
Expression of glucocorticoid receptor mRNAs in glucocorticoid-resistant nasal polyps. Exp Mol Med. 2006;
38(5):466–473.
91.
HarveyRHannanSABadiaL, et al.
Nasal saline irrigations for the symptoms of chronic rhinosinusitis.Cochrane Database Syst Rev. 2007;(3):CD006394.
92.
RamezanpourMRayanASmithJLP, et al.
The effect of topical treatments for CRS on the sinonasal epithelial barrier.Rhinology. 2017;
55:161–169.
93.
PrincipiNEspositoS.Nasal irrigation: an imprecisely defined medical procedure.Int J Environ Res Public Health. 2017;
14:E516.
94.
WoodsCMTanSUllahS, et al.
The effect of nasal irrigation formulation on the antimicrobial activity of nasal secretions.Int Forum Allergy Rhinol. 2015;
5:1104–1110.
95.
ParkSKJinYDParkYK, et al.
IL-25-induced activation of nasal fibroblast and its association with the remodeling of chronic rhinosinusitis with nasal polyposis. PLoS One. 2017;
12:e0181806.
96.
KohanskiMAWorkmanADPatelNN, et al.
Solitary chemosensory cells are a primary epithelial source of IL-25 in patients with chronic rhinosinusitis with nasal polyps.J Allergy Clin Immunol. 2018;
142:460–469.e467.
97.
HongHYChenFHSunYQ, et al.
Local IL-25 contributes to Th2-biased inflammatory profiles in nasal polyps.Allergy. 2018;
73:459–469.
98.
ShinHWKimDKParkMH, et al.
IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis.J Allergy Clin Immunol. 2015;
135:1476–1485.e1477.
99.
CameloABarlowJLDrynanLF, et al.
Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13.J Gastroenterol. 2012;
47:1198–1211.
100.
GregoryLGJonesCPWalkerSA, et al.
IL-25 drives remodelling in allergic airways disease induced by house dust mite.Thorax. 2013;
68:82–90.
